Rchr
J-GLOBAL ID:200901076859582910
Update date: Aug. 30, 2024
Nakai Yasuhiro
ナカイ ヤスヒロ | Nakai Yasuhiro
Affiliation and department:
Research field (1):
Medical equipment testing
Papers (23):
-
Akihito Tanaka, Kazuhiro Furuhashi, Kumiko Fujieda, Asuka Horinouchi, Kayaho Maeda, Shoji Saito, Tetsushi Mimura, Yosuke Saka, Tomohiko Naruse, Takuji Ishimoto, et al. Safety and Tolerability of ADR-001 Therapy for Immunoglobulin A Nephropathy. Kidney360. 2024
-
Takayuki Kitasaka, Shota Nakamura, Yuichiro Hayashi, Tsuyoshi Nakai, Yasuhiro Nakai, Kensaku Mori, Toyofumi Fengshi Chen-Yoshikawa. Development of panorama vision ring for thoracoscopy. International journal of computer assisted radiology and surgery. 2023. 18. 5. 945-952
-
Masaki Matsushita, Hiroshi Kitoh, Kenichi Mishima, Yasunari Kamiya, Daisaku Kato, Genta Takemoto, Kenta Sawamura, Shinji Ueno, Nakai Yasuhiro, Kazuki Nishida, et al. Phase 1b study on the repurposing of meclizine hydrochloride for children with achondroplasia. PloS one. 2023. 18. 7. e0283425
-
Akihito Tanaka, Kazuhiro Furuhashi, Kumiko Fujieda, Kayaho Maeda, Shoji Saito, Tetsushi Mimura, Yosuke Saka, Tomohiko Naruse, Takuji Ishimoto, Tomoki Kosugi, et al. Protocol for a Phase 1, Open-Label, Multiple-Center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 in the Treatment of Immunoglobulin A Nephropathy. Frontiers in medicine. 2022. 9. 883168-883168
-
Hiroshi Kitoh, Masaki Matsushita, Kenichi Mishima, Tadashi Nagata, Yasunari Kamiya, Kohei Ueda, Yachiyo Kuwatsuka, Hiroshi Morikawa, Yasuhiro Nakai, Naoki Ishiguro. Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. PloS one. 2020. 15. 4. e0229639
more...
MISC (22):
-
地野之浩, 宮田敦徳, 長谷川雅俊, 八馬賢次, 森治之, 堀内伸子, 安平明公, 神宮茂司, 坂井壮一, 寒川能成, et al. SGLT2阻害剤ルセオグリフロジンの代謝経路及び代謝酵素. 糖尿病. 2015. 58. Suppl.1. S-174
-
深沢芳樹, 長谷川雅俊, 間野陽子, 地野之浩, 坂東香久美, 宮田敦徳, 中井康博, 山口順一. 選択的SGLT2阻害剤ルセオグリフロジンのヒト薬物トランスポーターを介した薬物間相互作用の評価. 日本薬学会年会要旨集(CD-ROM). 2014. 134年会. 4. 128-128
-
中井康博. 早期探索臨床試験への企業からの期待. HAB研究機構学術年会プログラム・要旨集. 2012. 19th. 72-74
-
武藤賢, 水井信夫, 中井康博, 寒川能成, 坂井荘一, 渡辺隆. 新規選択的SGLT2阻害剤TS-071薬物相互作用の検討. 臨床薬理. 2011. 42. Suppl. S345-S345
-
Kato Koji, Kusuhara Hiroyuki, Mori Haruyuki, Nakai Yasuhiro, Sugiyama Yuichi. METABONOMIC APPROACH FOR IDENTIFYING ENDOGENOUS AND FOOD-DERIVED SUBSTRATES OF MRP2 IN RATS. Abstracts of Annual meeting of Japanese Society for the Study of Xenobiotics. 2010. 25. 0. 147-147
more...
Patents (2):
Education (2):
- 2005 - 2008 Nagoya City University Graduate school of pharmaceutical sciences
- 1981 - 1985 Kanazawa University Faculty of sciences Department of chemistry
Professional career (1):
Work history (4):
- 2019 - 2024/03 Nagoya University Hospital, Exploratory Oncology Research & Clinical Trial
- 2007 - 2018 Taisho Pharmaceutical co.ltd. Development headquarter Deputy head
- 1998 - 2007 Pfizer Global Research and Development Nagoya, PDM strategy Assosiate Director
- 1985 - 1998 Mochida Pharmaceutical Fuji Central Research, Discovery DMPK Cheif
Return to Previous Page